HCV E1E2MF59
Alternative Names: E1E2MF59; HCV/MF59Latest Information Update: 04 May 2009
At a glance
- Originator Chiron Corporation
- Developer Novartis
- Class Hepatitis C vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 26 Apr 2009 Phase-I/II clinical trials in Hepatitis C in Italy (Injection)
- 26 Apr 2009 Final efficacy data from a phase Ib trial in patients with Hepatitis C infection who did not respond or relapsed after standard therapy presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
- 01 Jan 2008 Coley Pharmaceutical Group has been acquired by Pfizer